Company strategy:

　　1. Business strategy: Driven by drug R&D and innovation, engage in the operation of APIs and pharmaceutical preparations, including technology investment and self-sustained sales of products.

　　2. Product strategy: Focus on difficult iron deficiency anemia and anticancer drugs, and appropriately involve other products with high technical difficulty and high cost control requirements.

　　3. Company business objectives

　　Five-year goal: By 2025, the annual net profit is not less than 20 million, and the company's valuation is not less than 300 million;

　　10-year goal: By 2030, the net profit will not be less than 50 million, the company's valuation will not be less than 1 billion, and it will meet the requirements of a listed company.

　　Foreign investment model:

　　1. Technology investment in chemical plants or pharmaceutical plants

　　2. Purchase of chemical or pharmaceutical factories

　　External financing:

　　Requirement: The investor does not participate in the operation for the purpose of financial gains